Overview of Taris GemRIS, a Novel Drug Delivery System for Bladder Cancer.

Published

Journal Article

GemRIS, an implantable drug delivery system from Taris Biomedical that delivers continuous intravesical gemcitabine, shows potential for use in multiple bladder cancer settings. Ongoing and recently completed phase 1 trials in non-muscle-invasive as well as muscle-invasive bladder cancer are yielding promising preliminary results.

Full Text

Duke Authors

Cited Authors

  • Grimberg, DC; Shah, A; Inman, BA

Published Date

  • July 15, 2020

Published In

Volume / Issue

  • 6 / 4

Start / End Page

  • 620 - 622

PubMed ID

  • 31561993

Pubmed Central ID

  • 31561993

Electronic International Standard Serial Number (EISSN)

  • 2405-4569

Digital Object Identifier (DOI)

  • 10.1016/j.euf.2019.09.006

Language

  • eng

Conference Location

  • Netherlands